ADVANCENCT07498335
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 18 → 23 locations
- Minor Trial sites expanded: 12 → 18 locations
Notable Eligibility criteria expanded, about 40 words Show 5 more changesShow less
- Trial sites expanded: 9 → 12 locations
- Start date changed from estimate of Aug 26, 2026 to Aug 6, 2026
- Secondary endpoints: details revised at 1 of 6 entries
- Study description revised
- Publications: details revised at 1 of 1 entry
- Minor Trial sites expanded: 6 → 9 locationsv7
- Notable Recruitment opened
- Trial sites expanded: 2 → 6 locations
- Minor Study sites: 0 to 2v4
- Notable Primary completion pushed from Nov 29, 2030 to Sep 15, 2031
- Study completion pushed from Jan 31, 2031 to Dec 13, 2032
- Start date: Oct 2, 2026 to Aug 26, 2026
- Minor Publications: details revised at 1 of 1 entryv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Once daily oral administration of 0.75 mg atrasentan for 104 weeks
Oral administration of weight-based appropriate dose(s) (that may be modified based on emerging data) for 104 weeks
Oral administration of weight-based appropriate dose(s) (that may be modified based on emerging data) for 104 weeks
Oral administration of weight-based appropriate dose(s) (that may be modified based on emerging data) for 104 weeks
Drugs: Drug: Atrasentan
Sites
23 sites in 8 countries
France 4, Japan 4, Spain 4, United States 4, China 2, Colombia 2, Taiwan 2, South Korea 1